综上，我们同意《关于使用自有资金增加首次公开发行股票部分募投项目 投资规模的议案》。 根据《上市公司独立董事管理办法》（以下简称"《独董管理办法》"）、《上 海证券交易所科创板股票上市规则》（以下简称"《股票上市规则》"）等法律、法 规以及《上海皓元医药股份有限公司章程》（以下简称"《公司章程》"）、《上海皓 元医药股份有限公司独立董事工作制度》的有关规定，我们作为上海皓元医药股 份有限公司（以下简称"公司"）的独立董事，现对公司第三届董事会第三十一 次会议审议的《关于使用自有资金增加首次公开发行股票部分募投项目投资规模 的议案》发表独立意见如下： 公司本次使用自有资金增加募集资金投资项目（以下简称"募投项目"）"安 徽皓元药业有限公司年产 121.095 吨医药原料药及中间体建设项目（一期）"（以 下简称"一期项目"）的投资规模是根据募投项目的实际建设需求和公司经营发 展的实际需要做出的适当调整，有利于保障募投项目的顺利实施，符合公司业务 发展需要和长期发展战略，不会对公司的正常经营产生重大不利影响，公司根据 募投项目的实际情况和其他客观因素调整部分车间达到预定可使用状态日期的 事项不存在募投项目建设停滞或 ...

Group 1: Company Overview - Shanghai Haoyuan Pharmaceutical Co., Ltd. is listed under stock code 688131 and stock name Haoyuan Pharmaceutical [2][3] - The company is located at 1999 Zhangheng Road, Building 3, Pudong New District, Shanghai, 201203 [1][4] Group 2: Q3 2023 Financial Performance - For the first three quarters of 2023, the company achieved total operating revenue of 1.376 billion CNY, an increase of 41.84% compared to the same period last year [4] - In Q3 2023 alone, the company reported operating revenue of 495 million CNY, reflecting a year-on-year growth of 41.95% [4] - The front-end business generated revenue of 232 million CNY, up 30.26% year-on-year; while tool compounds revenue reached 620 million CNY, increasing by 46.49% [4] - The back-end business saw innovative drug revenue of 331 million CNY, a growth of 54.40%, and generic drug revenue of 184 million CNY, up 25.60% [4]

上海皓元医药股份有限公司 上海皓元医药股份有限公司 投资者关系活动记录表 （2023 年第三季度业绩说明会） 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 | | 召开情况和交流内容请登录上证路演中心（网址：http:// | | --- | --- | | | roadshow.sseinfo.com/）进行查阅。 | | | 二、问答环节 | | | 1、请问 2023 三季度营收增加的原因是什么？ | | | 回答：尊敬的投资者您好，2023 年前三季度，公司实现营业总收入 | | | 13.76 亿元，较上年同期增长 41.84%。其中，单三季度，公司实现营业收 | | | 入 4.95 亿元，同比增长 41.95%。在生物医药市场阶段性调整及国内同行业 | | | 公司出现营收增速放缓的背景下，公司业务仍保持稳健增长，主要系公司 | | | 前后端业务均保持快速发展态势。前三季度，公司前端业务分子砌块收入 | | | 2.32 亿元，同比增长 30.26%；工具化合物收入 6.2 亿元，同比增长 | | | 46.49%。后端业务创新药收入 3.31 亿元，同比增长 54.4 ...

上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 （2023年11月） R特定对象调研 □分析师会议 投资者关系活动 £媒体采访 £业绩说明会 类别 □新闻发布会 ☑路演活动 □现场参观 £其他（电话会议、论坛） 国金证券、宸宝投资、国泰基金、上海汇正、民生证券、平安养老、浙商基 参与单位名称 金、国泰基金、浙商证券、国联基金、中欧基金 时间 2023年11月13日-14日 ...

上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 （2023年11月） R特定对象调研 □分析师会议 投资者关系活动 £媒体采访 £业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 £其他（电话会议、论坛） 开源证券、鹏华基金、中信证券、融通基金、中信建投证券、国华人寿、东海 参与单位名称 资管、华鑫证券 时间 2023年11月8日-9日 ...

上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 （2023年11月） R特定对象调研 □分析师会议 投资者关系活动 £媒体采访 £业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 £其他（电话会议、论坛） 开源证券、兴银理财、平安证券、摩根华鑫基金、国海证券、财通基金 参与单位名称 时间 2023年11月3日-7日 ...

上海皓元医药股份有限公司 股票代码：688131 股票名称：皓元医药 上海皓元医药股份有限公司 投资者关系活动记录表 （2023年10月） £特定对象调研 □分析师会议 投资者关系活动 £媒体采访 R业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 £其他（电话会议、论坛） 民生证券、海通证券、华西证券、太平洋证券、兴业证券、中泰证券、亚太财 参与单位名称 险、东海证券资管、华富基金、方正资管、诺安基金、平安养老保险、富达基 金、施罗德资管、国赞投资、光大保德信基金、国联安基金、嘉实基金、德邦 基金、深圳前海云溪基金、中信证券、中欧基金、南京证券、圆信永丰基金、 金元顺安基金、上海同犇投资、上海东方证券资管、东方证券自营、前海开 ...

Financial Performance - The company's revenue for Q3 2023 was CNY 495,195,752.26, representing a year-over-year increase of 41.95%[6] - The net profit attributable to shareholders for Q3 2023 was CNY 23,308,794.63, a decrease of 43.79% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 21,414,778.09, down 33.16% year-over-year[6] - Total operating revenue for the first three quarters of 2023 reached ¥1,376,113,868.75, a significant increase from ¥970,166,270.34 in the same period of 2022, representing a growth of approximately 42%[27][28] - Net profit for the first three quarters of 2023 was ¥116,758,100.59, down from ¥155,926,398.04 in 2022, reflecting a decrease of approximately 25.1%[29] - The company reported a total comprehensive income of ¥119,459,751.34 for the third quarter of 2023, down from ¥161,633,635.24 in the same quarter of 2022, indicating a decrease of about 26%[30] Research and Development - The total R&D investment for Q3 2023 was CNY 63,523,559.91, which accounted for 12.83% of the revenue, a decrease of 4.04 percentage points from the previous year[7] - Research and development expenses for the first three quarters of 2023 were ¥171,910,538.46, compared to ¥141,552,468.37 in 2022, marking an increase of approximately 21.4%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,755[13] - The largest shareholder, Shanghai Anxu Information Technology Co., Ltd., holds 48,630,632 shares, accounting for 32.34% of the total shares[13] - The second-largest shareholder, Junxin (Shanghai) Equity Investment Management Co., Ltd., holds 10,744,524 shares, representing 7.14% of the total shares[14] - The third-largest shareholder, Hong Kong Central Clearing Limited, holds 6,582,747 shares, which is 4.38% of the total shares[14] - The total number of shares held by the top ten shareholders includes significant stakes from various investment firms, indicating concentrated ownership[15] - The report highlights that 1,960,000 shares are held by Ningbo Chenxi Investment Partnership, accounting for 1.30% of the total shares[15] - The report indicates that there are no shares under pledge or freeze for the top shareholders[14] - The company has a diverse shareholder base, with significant holdings from both domestic and foreign investment entities[16] Assets and Liabilities - The company's total assets at the end of Q3 2023 were CNY 4,120,202,470.32, an increase of 14.52% from the end of the previous year[7] - As of September 30, 2023, the company's total assets reached CNY 4,120,202,470.32, an increase from CNY 3,597,744,539.58 at the end of 2022, reflecting a growth of approximately 14.5%[22] - The company's current assets totaled CNY 2,146,861,070.21, up from CNY 1,822,869,836.48 at the end of 2022, indicating an increase of about 17.8%[22] - The total liabilities as of the end of the third quarter of 2023 amounted to ¥1,642,885,284.38, up from ¥1,265,778,968.40 in the previous year, indicating an increase of about 29.7%[28] - The total current liabilities reached approximately $822.06 million, highlighting the company's short-term financial obligations[38] - Long-term borrowings stood at $170.90 million, contributing to the overall non-current liabilities of about $443.72 million[38] Cash Flow - The cash flow from operating activities for the year-to-date period was negative CNY 193,898,787.78, indicating challenges in cash generation[7] - Cash inflow from operating activities for the first three quarters of 2023 totaled ¥1,313,563,510.84, an increase from ¥938,702,783.47 in 2022, representing a growth of approximately 40%[31] - Cash outflow from operating activities totaled CNY 1,507,462,298.62, an increase from CNY 1,087,244,587.46 in the previous year, resulting in a net cash flow from operating activities of -CNY 193,898,787.78 compared to -CNY 148,541,803.99[33] - Cash inflow from investment activities was CNY 765,062,211.95, significantly lower than CNY 2,362,178,677.98 in the same period last year, leading to a net cash flow from investment activities of -CNY 294,104,131.83, compared to -CNY 546,851,103.07 previously[33] - Cash inflow from financing activities amounted to CNY 595,246,241.58, up from CNY 203,973,233.87 in the prior year, resulting in a net cash flow from financing activities of CNY 342,070,087.66, compared to CNY 129,014,429.99 last year[34] Operational Challenges - The company experienced a decline in gross margins due to increased competition and pricing pressures in the market[10] - The company plans to expand its product lines and enhance inventory management to address market demands and improve operational efficiency[11] Stock and Incentive Plans - The company granted 1,100,000 restricted stocks at a price of CNY 32.00 per share to 124 eligible participants as part of its 2023 incentive plan[19] - The total number of shares increased from 150,217,339 to 150,387,339 following the completion of the first category of restricted stock grant[20] - The company adjusted the grant price of the 2022 incentive plan from CNY 78.19 to CNY 55.58, and the total unvested shares increased from 1,017,817 to 1,424,944[21] Accounting and Reporting Changes - The company has implemented new accounting standards starting from 2023, which may affect the financial reporting and asset valuation going forward[34]

民生证券股份有限公司 关于上海皓元医药股份有限公司 首次公开发行股票部分募投项目结项并将节余资金用于其他募投项目 的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为上海皓元医药 股份有限公司（以下简称"公司"或"皓元医药"）首次公开发行股票并在科创板上市的 保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《科创板上市公司持续 监管办法（试行）》等有关法律法规和规范性文件的要求，民生证券对皓元医药首次公开 发行股票部分募投项目结项并将节余募集资金用于其他募投项目的事项进行了审慎核 查，发表如下核查意见： 一、首次公开发行股票募集资金投资项目概述 （一）首次公开发行股票募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海皓元医药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕1496 号）同意，公司首次向社会公众公开发 行人民币普通股（A 股）1,860.00 万股，每股发行价格为人民币 64 ...

证券代码：688131 证券简称：皓元医药 公告编号：2023-095 上海皓元医药股份有限公司 重要内容提示： 1、上海皓元医药股份有限公司（以下简称"公司"或"皓元医药"）根据 实际经营需要，拟采用售后回租的方式以新药研发相关设备与交银金融租赁有限 责任公司（以下简称"交银租赁"）进行融资租赁交易，租赁标的为公司新药研 发设备，融资金额不超过 8,000 万元，期限约为 36 个月，具体内容以公司与交 银租赁签订的最终协议为准。 2、公司于 2023 年 10 月 27 日召开的第三届董事会第三十次会议审议通过了 《关于公司拟开展融资租赁业务的议案》。公司独立董事对该事项发表了明确同 意的独立意见。 3、本事项不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。根据《上海证券交易所科创板股票上市规则》等相关法律 法规及《公司章程》等的规定，本次交易事项在公司董事会决策权限范围内，无 需提交公司股东大会审议。 一、交易概述 为适度利用融资渠道，优化融资结构，公司拟采用售后回租的方式以新药研 发相关设备与交银租赁进行融资租赁交易，融资金额不超过 8,000 万元，期限约 为 36 个 ...